Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73gamma in lung cancer

Stella Logotheti, Ioannis Michalopoulos, Maria Sideridou, Alexandros Daskalos, Sophia Kossida, Demetrios A. Spandidos, John K. Field, Borek Vojtesek, Triantafyllos Liloglou, Vassilis Gorgoulis, Vassilis Zoumpourlis

. 2010 ; 277 (14) : 3014-3027.

Jazyk angličtina Země Anglie, Velká Británie

Perzistentní odkaz   https://www.medvik.cz/link/bmc15000041

Grantová podpora
NS9812 MZ0 CEP - Centrální evidence projektů

Digitální knihovna NLK
Plný text - Článek
Zdroj

E-zdroje Online Plný text

NLK Free Medical Journals od 2005 do Před 1 rokem
Medline Complete (EBSCOhost) od 2005-01-01 do Před 1 rokem
Wiley Online Library (archiv) od 1967-01-01 do 2012-12-31
Wiley Free Content od 2005 do Před 1 rokem

Odkazy

PubMed 20528922
DOI 10.1111/j.1742-4658.2010.07710.x
Knihovny.cz E-zdroje

The p73 gene possesses an extrinsic P1 promoter and an intrinsic P2 promoter, resulting in TAp73 and DeltaNup73 isoforms, respectively. The ultimate effect of p73 in oncogenesis is thought to depend on the apoptotic TA to antiapoptotic DeltaN isoforms' ratio. This study was aimed at identifying novel transcription factors that affect TA isoform synthesis. With the use of bioinformatics tools, in vitro binding assays, and chromatin immunoprecipitation analysis, a region extending -233 to -204 bp upstream of the transcription start site of the human p73 P1 promoter, containing conserved Sp1-binding sites, was characterized. Treatment of cells with Sp1 RNAi and Sp1 inhibitor functionally suppress TAp73 expression, indicating positive regulation of P1 by the Sp1 protein. Notably Sp1 inhibition or knockdown also reduces DeltaNup73 protein levels. Therefore, Sp1 directly regulates TAp73 transcription and affects DeltaNup73 levels in lung cancer. TAp73gamma was shown to be the only TA isoform overexpressed in several lung cancer cell lines and in 26 non-small cell lung cancers, consistent with Sp1 overexpression, thereby questioning the apoptotic role of this specific p73 isoform in lung cancer.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15000041
003      
CZ-PrNML
005      
20170424113028.0
007      
ta
008      
150106s2010 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/j.1742-4658.2010.07710.x $2 doi
035    __
$a (PubMed)20528922
040    __
$a ABA008 $d ABA008 $e AACR2 $b cze
041    0_
$a eng
044    __
$a enk
100    1_
$a Logotheti, Stella $u Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece
245    10
$a Sp1 binds to the external promoter of the p73 gene and induces the expression of TAp73gamma in lung cancer / $c Stella Logotheti, Ioannis Michalopoulos, Maria Sideridou, Alexandros Daskalos, Sophia Kossida, Demetrios A. Spandidos, John K. Field, Borek Vojtesek, Triantafyllos Liloglou, Vassilis Gorgoulis, Vassilis Zoumpourlis
520    9_
$a The p73 gene possesses an extrinsic P1 promoter and an intrinsic P2 promoter, resulting in TAp73 and DeltaNup73 isoforms, respectively. The ultimate effect of p73 in oncogenesis is thought to depend on the apoptotic TA to antiapoptotic DeltaN isoforms' ratio. This study was aimed at identifying novel transcription factors that affect TA isoform synthesis. With the use of bioinformatics tools, in vitro binding assays, and chromatin immunoprecipitation analysis, a region extending -233 to -204 bp upstream of the transcription start site of the human p73 P1 promoter, containing conserved Sp1-binding sites, was characterized. Treatment of cells with Sp1 RNAi and Sp1 inhibitor functionally suppress TAp73 expression, indicating positive regulation of P1 by the Sp1 protein. Notably Sp1 inhibition or knockdown also reduces DeltaNup73 protein levels. Therefore, Sp1 directly regulates TAp73 transcription and affects DeltaNup73 levels in lung cancer. TAp73gamma was shown to be the only TA isoform overexpressed in several lung cancer cell lines and in 26 non-small cell lung cancers, consistent with Sp1 overexpression, thereby questioning the apoptotic role of this specific p73 isoform in lung cancer.
590    __
$a bohemika - dle Pubmed
650    02
$a sekvence nukleotidů $x genetika $7 D001483
650    02
$a vazebná místa $x genetika $7 D001665
650    02
$a nádorové buněčné linie $7 D045744
650    02
$a výpočetní biologie $7 D019295
650    02
$a konzervovaná sekvence $x genetika $7 D017124
650    02
$a DNA $x chemie $7 D004247
650    02
$a DNA $x metabolismus $7 D004247
650    12
$a DNA vazebné proteiny $x genetika $7 D004268
650    02
$a DNA vazebné proteiny $x metabolismus $7 D004268
650    02
$a down regulace $x genetika $7 D015536
650    02
$a retardační test $7 D024202
650    _2
$a lidé $7 D006801
650    12
$a nádory plic $x metabolismus $7 D008175
650    02
$a molekulární sekvence - údaje $7 D008969
650    12
$a jaderné proteiny $x genetika $7 D009687
650    02
$a jaderné proteiny $x metabolismus $7 D009687
650    02
$a oligodeoxyribonukleotidy $x genetika $7 D009838
650    02
$a oligodeoxyribonukleotidy $x metabolismus $7 D009838
650    02
$a mithramycin $x analogy a deriváty $7 D008926
650    02
$a mithramycin $x farmakologie $7 D008926
650    12
$a promotorové oblasti (genetika) $x genetika $7 D011401
650    02
$a vazba proteinů $x genetika $7 D011485
650    02
$a protein - isoformy $x genetika $7 D020033
650    12
$a protein - isoformy $x metabolismus $7 D020033
650    02
$a malá interferující RNA $x genetika $7 D034741
650    02
$a transkripční faktor Sp1 $x antagonisté a inhibitory $7 D016329
650    02
$a transkripční faktor Sp1 $x genetika $7 D016329
650    12
$a transkripční faktor Sp1 $x metabolismus $7 D016329
650    12
$a nádorové supresorové proteiny $x genetika $7 D025521
650    02
$a nádorové supresorové proteiny $x metabolismus $7 D025521
650    02
$a vaskulární endoteliální růstový faktor A $x metabolismus $7 D042461
700    1_
$a Michalopoulos, Ioannis $u Bioinformatics & Medical Informatics, Foundation for Biomedical Research of the Academy of Athens, Greece
700    1_
$a Sideridou, Maria $u Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School of Athens, Greece
700    1_
$a Daskalos, Alexandors $u Roy Castle Lung Cancer Research Programme, Division of Surgery and Oncology, University of Liverpool Cancer Research Centre, University of Liverpool, UK
700    1_
$a Kossida, Sophia $u Bioinformatics & Medical Informatics, Foundation for Biomedical Research of the Academy of Athens, Greece
700    1_
$a Spandidos, Demetrios A. $u Laboratory of Clinical Virology, Faculty of Medicine, University of Crete, Heraklion, Greece
700    1_
$a Field, John K. $u Roy Castle Lung Cancer Research Programme, Division of Surgery and Oncology, University of Liverpool Cancer Research Centre, University of Liverpool, UK
700    1_
$a Vojtesek, Borek $u Department of Oncological and Experimental Pathology, Masaryk Memorial Cancer Institute, Brno, Czech Republic
700    1_
$a Liloglou, Triantafyllos $u Roy Castle Lung Cancer Research Programme, Division of Surgery and Oncology, University of Liverpool Cancer Research Centre, University of Liverpool, UK
700    1_
$a Gorgoulis, Vassilis $u Molecular Carcinogenesis Group, Department of Histology and Embryology, Medical School of Athens, Greece
700    1_
$a Zoumpourlis, Vassilis $u Institute of Biological Research and Biotechnology, National Hellenic Research Foundation, Athens, Greece
773    0_
$t The FEBS journal $x 1742-464X $g Roč. 277, č. 14 (2010), s. 3014-3027 $w MED00008414
910    __
$a ABA008 $y 4 $z 0
990    __
$a 20150106115536 $b ABA008
991    __
$a 20170424113344 $b ABA008
999    __
$a ok $b bmc $g 1057066 $s 882759
BAS    __
$a 3
BMC    __
$a 2010 $b 277 $c 14 $d 3014-3027 $i 1742-464X $m The FEBS journal $x MED00008414
GRA    __
$a NS9812 $p MZ0
LZP    __
$a 2015-01/ab

Najít záznam

Citační ukazatele

Možnosti archivace